Data / Drug companies / Dalfampridine
Dalfampridine: 11 companies and 11 products in the FDA NDC directory
Dalfampridine is listed in the FDA National Drug Code Directory by 11 companies, with 11 products in commercial distribution. 9 of the products (81.8%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated, extended release; tablet, extended release, and the newest product started marketing on July 21, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 11
- Generic (ANDA) products
- 9 (81.8%)
- Application numbers
- 7
- Routes
- Oral
- Brand names
- Ampyra
- openFDA record search
- api.fda.gov
Companies that list dalfampridine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Accord Healthcare Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | September 18, 2018 |
| Actavis Pharma, Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | May 31, 2022 |
| Ascend Laboratories, LLC | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | July 31, 2018 |
| Aurobindo Pharma Limited | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | June 25, 2018 |
| Bryant Ranch Prepack | 1 | tablet, extended release | Generic drugs (ANDA) | March 21, 2019 |
| CivicaScript LLC | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | July 21, 2025 |
| Golden State Medical Supply, Inc. | 1 | tablet, film coated, extended release | Generic drugs (ANDA) | July 30, 2018 |
| Merz Pharmaceuticals, LLC | 1 | tablet, film coated, extended release | New drug applications (NDA) | March 1, 2010 |
| Merz Pharmaceuticals, LLC | 1 | tablet, film coated, extended release | New drug applications (NDA) | March 1, 2010 |
| Micro Labs Limited | 1 | tablet, extended release | Generic drugs (ANDA) | March 21, 2019 |
| Sun Pharmaceutical Industries, Inc. | 1 | tablet, extended release | Generic drugs (ANDA) | May 22, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated, extended release | 8 | 72.7% |
| Tablet, extended release | 3 | 27.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 9 | 81.8% |
| New drug applications (NDA) | 2 | 18.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Potassium Channel Blocker | 11 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.